Multiplicom launches non-invasive test to detect Down's

October 26, 2015 News BioVox

Multiplicom (Niel) launched a new non-invasive prenatal test (NIPT), Clarigo™, based on a blood sample. Genetic analysis of the baby’s DNA, which is present in the blood of the mother, enables the detection of Down’s syndrome (trisomy 21), Edwards’ syndrome (trisomy 18) and Patau syndrome (trisomy 13). This test can be performed as early as 8 weeks into pregnancy.

Thanks to the increased sensitivity and reliability of this test compared to the current test to detect trisomy, a large number of pregnant women will be spared from the invasive amniocentesis procedure. If a genetic abnormality is found, the pregnant woman will be referred to the classic invasive procedure to confirm the result.

Multiplicom hopes to include the test in the current prenatal testing program for pregnant women. “The test will provide much greater reassurance and comfort during pregnancy,” says Dirk Pollet, CEO of Multiplicom.

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts